{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(4)"],"submitter":["Soldatos TG"],"pubmed_abstract":["Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their saf"],"journal":["Diagnostics (Basel, Switzerland)"],"pagination":["E76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6316083"],"repository":["biostudies-literature"],"pubmed_title":["Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data."],"pmcid":["PMC6316083"],"pubmed_authors":["Larribere L","Dimitrakopoulou-Strauss A","Hassel JC","Sachpekidis C","Soldatos TG"],"additional_accession":[]},"is_claimable":false,"name":"Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.","description":"Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their saf","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-04-04T12:41:29.935Z","creation":"2019-03-26T22:36:05Z"},"accession":"S-EPMC6316083","cross_references":{"pubmed":["30384507"],"doi":["10.3390/diagnostics8040076"]}}